Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12009MR)

This product GTTS-WQ12009MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12009MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2937MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ13319MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ8858MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ11228MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ10963MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ4734MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ13676MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ14528MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SA-237
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW